Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Knockout of microRNA-21 attenuates alcoholic hepatitis through the VHL/NF-κB signaling pathway in hepatic stellate cells.

Wu N, McDaniel K, Zhou T, Ramos-Lorenzo S, Wu C, Huang L, Chen D, Annable T, Francis H, Glaser S, Alpini G, Meng F.

Am J Physiol Gastrointest Liver Physiol. 2018 Sep 1;315(3):G385-G398. doi: 10.1152/ajpgi.00111.2018. Epub 2018 May 31.

2.

Regulation of Cellular Senescence by miR-34a in Alcoholic Liver Injury.

Wan Y, McDaniel K, Wu N, Ramos-Lorenzo S, Glaser T, Venter J, Francis H, Kennedy L, Sato K, Zhou T, Kyritsi K, Huang Q, Annable T, Wu C, Glaser S, Alpini G, Meng F.

Am J Pathol. 2017 Dec;187(12):2788-2798. doi: 10.1016/j.ajpath.2017.08.027. Epub 2017 Nov 8.

3.

The let-7/Lin28 axis regulates activation of hepatic stellate cells in alcoholic liver injury.

McDaniel K, Huang L, Sato K, Wu N, Annable T, Zhou T, Ramos-Lorenzo S, Wan Y, Huang Q, Francis H, Glaser S, Tsukamoto H, Alpini G, Meng F.

J Biol Chem. 2017 Jul 7;292(27):11336-11347. doi: 10.1074/jbc.M116.773291. Epub 2017 May 23.

4.

Adsorption of Small Cationic Nanoparticles onto Large Anionic Particles from Aqueous Solution: A Model System for Understanding Pigment Dispersion and the Problem of Effective Particle Density.

North SM, Jones ER, Smith GN, Mykhaylyk OO, Annable T, Armes SP.

Langmuir. 2017 Feb 7;33(5):1275-1284. doi: 10.1021/acs.langmuir.6b04541. Epub 2017 Jan 24.

5.

Role of stem cells during diabetic liver injury.

Wan Y, Garner J, Wu N, Phillip L, Han Y, McDaniel K, Annable T, Zhou T, Francis H, Glaser S, Huang Q, Alpini G, Meng F.

J Cell Mol Med. 2016 Feb;20(2):195-203. doi: 10.1111/jcmm.12723. Epub 2015 Dec 9. Review.

6.

Using Poly I:C as an adjuvant does not induce or exacerbate models of systemic lupus erythematosus.

Annable T, Tomassian T, Jain S, Leibbrandt M, Cooke MP, Deane JA.

Autoimmunity. 2015 Feb;48(1):29-39. doi: 10.3109/08916934.2014.959166. Epub 2014 Dec 8.

PMID:
25483245
7.

Alpha-mercaptoketone based histone deacetylase inhibitors.

Wash PL, Hoffman TZ, Wiley BM, Bonnefous C, Smith ND, Sertic MS, Lawrence CM, Symons KT, Nguyen PM, Lustig KD, Guo X, Annable T, Noble SA, Hager JH, Hassig CA, Malecha JW.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6482-5. doi: 10.1016/j.bmcl.2008.10.058. Epub 2008 Oct 17.

PMID:
18954984
8.

Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.

Payne JE, Bonnefous C, Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Hoffman TZ, Rao TS, Shiau AK, Malecha JW, Noble SA, Hager JH, Smith ND.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6093-6. doi: 10.1016/j.bmcl.2008.10.029. Epub 2008 Oct 11.

PMID:
18954983
9.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.

Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Payne JE, Jenkins DA, Bonnefous C, Trotter C, Wang Y, Anzola JV, Milkova EL, Hoffman TZ, Dozier SJ, Wiley BM, Saven A, Malecha JW, Davis RL, Muhammad J, Shiau AK, Noble SA, Rao TS, Smith ND, Hager JH.

Mol Cancer Ther. 2008 May;7(5):1054-65. doi: 10.1158/1535-7163.MCT-07-2347.

10.

Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus.

Sadler TM, Gavriil M, Annable T, Frost P, Greenberger LM, Zhang Y.

Endocr Relat Cancer. 2006 Sep;13(3):863-73.

PMID:
16954435
11.

Luminescence techniques and characterization of the morphology of polymer latices 2. Fluorescence lifetime, phosphorescence and fluorescence anisotropy studies.

Soutar I, Swanson L, Annable T, Padget JC, Satgurunathan R.

J Colloid Interface Sci. 2006 Nov 1;303(1):205-13. Epub 2006 Jul 22.

PMID:
16919664
13.
14.

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.

Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, Nettles JH, Snyder JP, Greenberger LM.

Mol Cancer Ther. 2006 Feb;5(2):270-8.

15.

2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.

Wissner A, Floyd MB, Johnson BD, Fraser H, Ingalls C, Nittoli T, Dushin RG, Discafani C, Nilakantan R, Marini J, Ravi M, Cheung K, Tan X, Musto S, Annable T, Siegel MM, Loganzo F.

J Med Chem. 2005 Dec 1;48(24):7560-81.

PMID:
16302797
16.

Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.

Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, Fojo T.

Biochemistry. 2004 Nov 9;43(44):13944-54.

PMID:
15518543
17.

Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, Zask A, Kaplan J, Minnick AA Jr, May MK, Ayral-Kaloustian S, Poruchynsky MS, Fojo T, Greenberger LM.

Mol Cancer Ther. 2004 Oct;3(10):1319-27.

18.

Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment.

Yamashita A, Norton EB, Kaplan JA, Niu C, Loganzo F, Hernandez R, Beyer CF, Annable T, Musto S, Discafani C, Zask A, Ayral-Kaloustian S.

Bioorg Med Chem Lett. 2004 Nov 1;14(21):5317-22.

PMID:
15454219
19.

Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286).

Zask A, Birnberg G, Cheung K, Kaplan J, Niu C, Norton E, Suayan R, Yamashita A, Cole D, Tang Z, Krishnamurthy G, Williamson R, Khafizova G, Musto S, Hernandez R, Annable T, Yang X, Discafani C, Beyer C, Greenberger LM, Loganzo F, Ayral-Kaloustian S.

J Med Chem. 2004 Sep 9;47(19):4774-86.

PMID:
15341492
20.

MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.

Sampath D, Discafani CM, Loganzo F, Beyer C, Liu H, Tan X, Musto S, Annable T, Gallagher P, Rios C, Greenberger LM.

Mol Cancer Ther. 2003 Sep;2(9):873-84.

21.

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM.

Cancer Res. 2003 Apr 15;63(8):1838-45.

23.

Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.

Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T, Greenberger LM.

Cancer Res. 1998 Dec 15;58(24):5850-8.

25.

P-glycoprotein mediates profound resistance to bisantrene.

Zhang XP, Ritke MK, Yalowich JC, Slovak ML, Ho JP, Collins KI, Annable T, Arceci RJ, Durr FE, Greenberger LM.

Oncol Res. 1994;6(7):291-301.

PMID:
7865904

Supplemental Content

Loading ...
Support Center